Total Payments
$72,209
2024 Payments
$66,536
Companies
30
Transactions
237
Medicare Patients
2,484
Medicare Billing
$218,267
Payment Breakdown by Category
Other$62,946 (87.2%)
Food & Beverage$8,450 (11.7%)
Travel$742.34 (1.0%)
Education$70.44 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $62,946 | 71 | 87.2% |
| Food and Beverage | $8,450 | 158 | 11.7% |
| Travel and Lodging | $742.34 | 5 | 1.0% |
| Education | $70.44 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $55,058 | 100 | $0 (2024) |
| Novo Nordisk Inc | $13,158 | 56 | $0 (2024) |
| Gilead Sciences, Inc. | $602.51 | 5 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $361.88 | 4 | $0 (2021) |
| IDORSIA PHARMACEUTICALS US INC | $263.20 | 4 | $0 (2024) |
| ViiV Healthcare Company | $246.77 | 2 | $0 (2018) |
| Sunovion Pharmaceuticals Inc. | $230.01 | 2 | $0 (2018) |
| Allergan Inc. | $211.10 | 2 | $0 (2019) |
| GlaxoSmithKline, LLC. | $206.44 | 13 | $0 (2023) |
| Abbott Laboratories | $192.16 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $66,536 | 123 | Lilly USA, LLC ($54,963) |
| 2023 | $1,088 | 29 | Novo Nordisk Inc ($498.04) |
| 2022 | $555.22 | 21 | Novo Nordisk Inc ($223.19) |
| 2021 | $701.24 | 19 | Novo Nordisk Inc ($275.68) |
| 2020 | $129.51 | 3 | Novo Nordisk Inc ($129.51) |
| 2019 | $1,127 | 15 | Novo Nordisk Inc ($590.28) |
| 2018 | $1,083 | 11 | Merck Sharp & Dohme Corporation ($140.03) |
| 2017 | $989.33 | 16 | Gilead Sciences Inc ($362.94) |
All Payment Transactions
237 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 12/18/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 12/17/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 12/16/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 12/13/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 12/11/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 12/10/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 12/10/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 12/03/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 12/02/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 11/27/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 11/21/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Endocrinology | ||||||
| 11/19/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 11/19/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 11/18/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 11/15/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 11/15/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 11/13/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: Obesity | ||||||
| 11/12/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 11/04/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 11/04/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $350.00 | General |
| Category: Obesity | ||||||
| 10/31/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 10/31/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 10/29/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 10/28/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 160 | 235 | $61,586 | $22,704 |
| 2022 | 13 | 715 | 966 | $145,695 | $69,957 |
| 2021 | 20 | 1,053 | 1,357 | $172,740 | $90,319 |
| 2020 | 10 | 556 | 644 | $91,018 | $35,287 |
Total Patients
2,484
Total Services
3,202
Medicare Billing
$218,267
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 60 | 112 | $26,681 | $9,916 | 37.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 39 | 55 | $18,443 | $6,375 | 34.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 34 | 41 | $6,906 | $2,792 | 40.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $4,643 | $1,898 | 40.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $4,913 | $1,722 | 35.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 133 | 255 | $47,375 | $21,240 | 44.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 82 | 111 | $31,802 | $15,082 | 47.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 110 | 110 | $17,600 | $14,536 | 82.6% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 22 | 22 | $16,899 | $6,134 | 36.3% |
| 90682 | Influenza vaccine, quadrivalent derived from recombinant dna | Office | 2022 | 41 | 41 | $4,763 | $2,732 | 57.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 43 | 52 | $5,904 | $2,508 | 42.5% |
| 77067 | Screening mammography | Office | 2022 | 16 | 16 | $6,445 | $2,129 | 33.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $4,286 | $1,797 | 41.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 42 | 42 | $1,314 | $1,179 | 89.7% |
| 77063 | Screening 3d breast mammography | Office | 2022 | 16 | 16 | $2,625 | $861.46 | 32.8% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 25 | 25 | $929.65 | $752.55 | 80.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 160 | 239 | $4,063 | $715.91 | 17.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 14 | 26 | $1,690 | $290.32 | 17.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 170 | 263 | $44,710 | $24,606 | 55.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 108 | 141 | $34,545 | $17,329 | 50.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 121 | 121 | $19,360 | $16,304 | 84.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 97 | 119 | $12,495 | $7,335 | 58.7% |
| 77067 | Screening mammography of both breasts | Office | 2021 | 32 | 32 | $11,136 | $4,381 | 39.3% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2021 | 19 | 19 | $4,370 | $3,246 | 74.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 20 | 20 | $7,100 | $3,239 | 45.6% |
About Dr. Sully Drotar, D.O
Dr. Sully Drotar, D.O is a Internal Medicine healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/28/2015. The National Provider Identifier (NPI) number assigned to this provider is 1861874703.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sully Drotar, D.O has received a total of $72,209 in payments from pharmaceutical and medical device companies, with $66,536 received in 2024. These payments were reported across 237 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($62,946).
As a Medicare-enrolled provider, Drotar has provided services to 2,484 Medicare beneficiaries, totaling 3,202 services with total Medicare billing of $218,267. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Obesity Medicine
- Location Dallas, TX
- Active Since 06/28/2015
- Last Updated 01/17/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1861874703
Products in Payments
- ZEPBOUND (Drug) $54,166
- Wegovy (Drug) $11,690
- Ozempic (Drug) $824.94
- Epclusa (Drug) $371.30
- QUVIVIQ (Drug) $263.20
- FARXIGA (Drug) $245.32
- JARDIANCE (Drug) $208.97
- SHINGRIX (Biological) $206.44
- Vascepa (Drug) $190.11
- MOUNJARO (Drug) $183.78
- ISENTRESS (Drug) $140.03
- Kerendia (Drug) $136.35
- FREESTYLE LIBRE 2 (Device) $133.23
- SAMSCA (Drug) $126.70
- TRIUMEQ (Drug) $124.90
- STELARA (Biological) $124.88
- Biktarvy (Drug) $124.84
- LONHALA MAGNAIR (Drug) $122.90
- MYDAYIS (Drug) $122.16
- JULUCA (Drug) $121.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Dallas
Andrew Whiteley
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Biff Palmer, Md, MD
Internal Medicine — Payments: $980,569
Internal Medicine $980,569
Dr. Robert Gottlieb, M.d. Ph.d, M.D. PH.D
Internal Medicine — Payments: $832,284
Internal Medicine $832,284
Dr. Ronan Kelly, Md, MD
Internal Medicine — Payments: $813,092
Internal Medicine $813,092
Dr. Gates Colbert, M.d, M.D
Internal Medicine — Payments: $801,349
Internal Medicine $801,349
Dr. Zoran Kurepa, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $743,379
Internal Medicine $743,379